Sodium Correction for Glucose: UK Clinical Guide

Sodium correction for glucose is an essential bedside calculation used whenever high blood sugar artificially lowers a patient's measured serum sodium. In hyperglycaemia, osmotic water shifts from cells into the bloodstream dilute the sodium concentration, producing a falsely low result known as translocational hyponatraemia. Without correcting for this effect, clinicians risk misinterpreting a normal or even elevated true sodium as dangerously low, leading to inappropriate fluid or electrolyte management. This article explains the mechanism, the correction formula used in UK practice, the choice of correction factor, and the clinical implications in conditions such as diabetic ketoacidosis and hyperosmolar hyperglycaemic state.

Why does high blood sugar affect your sodium level?

High blood glucose draws water out of cells by osmosis, expanding plasma volume and diluting serum sodium, producing translocational hyponatraemia without any true loss of body sodium.

High blood glucose causes a dilutional fall in measured serum sodium by drawing water out of cells and into the bloodstream through osmosis.^[1][5] Glucose is an osmotically active solute: when plasma glucose rises, the resulting osmotic gradient pulls intracellular water into the extracellular space, expanding plasma volume and diluting the sodium already present. The result is a measured sodium concentration that appears lower than the body's true sodium status, a phenomenon known as translocational (or dilutional) hyponatraemia.

This is distinct from pseudohyponatraemia, which is a laboratory artefact caused by marked hyperlipidaemia or hyperproteinaemia and is unrelated to hyperglycaemic water shifts. It is also distinct from true sodium depletion. In translocational hyponatraemia, the body's total sodium content may be normal or even elevated; the measured concentration appears low simply because of the extra water in the vascular compartment. Once glucose is corrected, whether through insulin therapy or rehydration, water shifts back into cells and the sodium concentration rises accordingly.

Understanding this mechanism is clinically important because acting on an uncorrected sodium result in a patient with severe hyperglycaemia can lead to inappropriate fluid or electrolyte management. Clinicians therefore apply a mathematical correction to estimate what the sodium would be at a normal glucose level, giving a more accurate picture of the patient's true sodium status.

How do doctors calculate corrected sodium in hyperglycaemia?

Corrected sodium is calculated by adding a correction factor multiplied by the glucose excess above 5.5 mmol/L divided by 5.5 to the measured sodium, transforming an apparently low result into a clinically accurate estimate.

Corrected sodium is calculated by adding a fixed increment to the measured sodium for every unit rise in plasma glucose above the normal reference range. The formula used in UK clinical practice is:

Corrected sodium (mmol/L) = Measured sodium + correction factor x [(plasma glucose in mmol/L minus 5.5) / 5.5]

In practical terms, the clinician takes the patient's measured serum sodium from the blood test, identifies how far the glucose exceeds the normal upper limit (approximately 5.5 mmol/L), and applies the chosen correction factor to estimate the true sodium concentration. The result is an estimate rather than a precise physiological measurement and should always be interpreted alongside the full clinical picture, including the patient's fluid status, symptoms and other electrolyte results.

For example, if a patient has a measured sodium of 128 mmol/L and a plasma glucose of 33 mmol/L, the glucose excess above 5.5 mmol/L is 27.5 mmol/L, which represents five increments of 5.5 mmol/L. Using a correction factor of 2.4 mmol/L per 5.5 mmol/L rise in glucose, the corrected sodium would be approximately 128 + (5 x 2.4) = 140 mmol/L, which is within the normal range.

This calculation transforms a seemingly alarming hyponatraemia into a normal or even elevated corrected value, fundamentally changing the clinical interpretation and subsequent management. It is a straightforward bedside calculation that requires only the two values already present on a standard biochemistry result.

What correction factor do UK clinicians use, and why does it matter?

UK clinicians commonly use 2.4 mmol/L per 5.5 mmol/L glucose increment, as this more accurately reflects osmotic dilution than the older 1.6 figure, particularly at glucose levels seen in DKA and HHS.

A correction factor of 2.4 mmol/L per 5.5 mmol/L increment in plasma glucose is widely used in UK clinical practice. This figure is supported by the work of Hillier and colleagues (1999), who demonstrated in a controlled study that the 2.4 mmol/L factor more accurately reflects the osmotic dilution of sodium across a range of glucose concentrations than the older figure of 1.6 mmol/L per 5.5 mmol/L rise. Readers should verify whether the most current JBDS DKA and HHS guidelines explicitly endorse a specific numerical factor, as guidance documents are updated periodically and the article's authors recommend consulting the latest published versions directly.

The choice of correction factor matters because it directly influences whether a patient's sodium is interpreted as low, normal or high. Using the lower 1.6 figure in a patient with severe hyperglycaemia may still suggest hyponatraemia when the corrected sodium is actually normal or hypernatraemic. The higher 2.4 figure more accurately reflects the osmotic dilution occurring at glucose levels commonly seen in diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS).

Some clinicians use a simplified approximation: add 2 mmol/L to the measured sodium for every 5.5 mmol/L that glucose exceeds the normal range. This is an approximation and its accuracy diminishes at very high glucose concentrations. Whichever factor is used, consistency within a clinical team and awareness of the formula's limitations are essential. The correction should always be interpreted alongside the full clinical picture, including the patient's fluid status, symptoms and other electrolyte results.

When is corrected sodium clinically significant in DKA and HHS?

Corrected sodium is recalculated at each set of blood results in DKA and HHS to guide fluid selection and monitor effective osmolality, which should not fall faster than 3 to 8 mmol/kg/hour in HHS.

Corrected sodium is particularly significant in DKA and HHS because the two conditions carry different sodium implications and require different fluid management strategies.

In both conditions, UK clinicians use calculated effective osmolality (approximately 2 x [sodium + potassium] + glucose, all in mmol/L) as the primary safety metric for monitoring treatment.^[2][5] JBDS guidance recommends that osmolality should not fall faster than 3 to 8 mmol/kg/hour in HHS, to reduce the risk of cerebral oedema and other neurological complications.^[2] Corrected sodium is one component of this assessment and should be recalculated at each set of blood results rather than relying on a single measurement.

In HHS, where plasma glucose can exceed 30 mmol/L and effective osmolality is markedly elevated, the corrected sodium helps assess the degree of hyperosmolality. JBDS guidance on HHS notes that patients often have a high corrected sodium, reflecting genuine hypernatraemia once the dilutional effect of glucose is accounted for. Fluid selection is guided by the clinical response: isotonic 0.9% sodium chloride is the standard initial resuscitation fluid, and a switch to 0.45% sodium chloride may be considered by the clinical team if osmolality is not falling adequately or if sodium is rising despite adequate fluid replacement, in line with JBDS HHS criteria.

In DKA, corrected sodium trends during treatment inform fluid titration alongside osmolality. Rapid correction of hyperosmolality carries a risk of cerebral oedema, particularly in children and young adults.^[8][9] NICE NG17 (Type 1 diabetes in adults) and NICE NG18 (Diabetes in children and young people) both address DKA management and emphasise careful fluid titration informed by electrolyte trends.^[6] Clinicians managing DKA or HHS should consult the current JBDS DKA and HHS guidelines directly for specific targets and monitoring intervals.

What are the risks of misinterpreting sodium results in high glucose states?

Treating dilutional hyponatraemia as true hyponatraemia without glucose correction can lead to inappropriate fluid restriction or hypertonic saline use, while missing a high corrected sodium can cause under-resuscitation and neurological harm.

Misinterpreting an uncorrected sodium result in a patient with severe hyperglycaemia carries several patient safety risks, the most serious of which is inappropriate treatment of apparent hyponatraemia. If a clinician treats a dilutional sodium of 125 mmol/L as true hyponatraemia without accounting for a glucose of 35 mmol/L, they may restrict fluids or administer hypertonic saline unnecessarily, worsening the patient's osmotic state and potentially causing harm.

Conversely, failing to recognise that a corrected sodium is actually elevated can lead to under-resuscitation or the use of fluids that are insufficiently hypotonic to correct genuine hypernatraemia in HHS. Both errors can contribute to adverse neurological outcomes, including cerebral oedema.

Osmotic demyelination syndrome is a recognised risk associated with overly rapid correction of chronic hyponatraemia (typically a rise in serum sodium exceeding 8 to 10 mmol/L per 24 hours in that context).^[10][11] In DKA and HHS, the primary neurological concern during treatment is cerebral oedema from rapid osmolality change rather than osmotic demyelination, though the direction and speed of sodium change remain important in both settings.

There is also a risk of overlooking concurrent true hyponatraemia. Not all hyponatraemia in a hyperglycaemic patient is dilutional: some patients may have coexisting sodium depletion from vomiting, diuretic use or renal losses. A corrected sodium that remains low after calculation warrants further investigation rather than automatic reassurance.

Suspected side effects, medication errors or medical device concerns related to treatment should be reported to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk). Broader clinical incidents and patient safety events should be reported through local governance processes and the NHS Learning from Patient Safety Events (LFPSE) service. Any clinician managing a patient with DKA or HHS who is uncertain about sodium interpretation should seek senior review promptly, and patients with symptoms such as confusion, severe headache or reduced consciousness in the context of known diabetes should be assessed in an emergency department without delay.

Scientific References

1. Hyponatremia: evaluating the correction factor for hyperglycemia (Hillier et al.).
2. Management of Hyperosmolar Hyperglycaemic State (HHS) in Adults: An updated guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care Group (Mustafa et al.).
3. Pseudohyponatremia: A Potentially Dangerous Laboratory Artifact (Amiri et al.).
4. Corrected Sodium Calculator (DKA) – Evelina London NHS / South Thames Retrieval Service.
5. Diabetic hyperglycaemic emergencies | Treatment summaries – BNF/NICE.
6. Type 1 diabetes in adults: diagnosis and management (NG17).
7. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18).
8. Risk Factors for Cerebral Edema in Children with Diabetic Ketoacidosis (Glaser et al.).
9. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children (Edge et al.).
10. Diagnosis and Management of Hyponatremia: A Review – JAMA.
11. Osmotic Demyelination Syndrome following Correction of Hyponatremia by ≤10 mEq/L per Day – Kidney360.
12. Evaluation of desmopressin in preventing overcorrection of hyponatraemia among patients with renal dysfunction – European Journal of Hospital Pharmacy.
13. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
14. Adverse reactions to drugs | Medicines guidance – BNF/NICE.

Frequently Asked Questions